Pharmacological therapies for Liposarcoma

Research output: Contribution to journalReview articlepeer-review


Introduction: Liposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients’ quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes.

Original languageEnglish
Pages (from-to)361-377
Number of pages17
JournalExpert Review of Clinical Pharmacology
Issue number4
Publication statusPublished - Apr 3 2017


  • CDK4
  • chemotherapy
  • clinical trials
  • eribulin
  • MDM2
  • myxoid liposarcoma
  • pleomorphic liposarcoma
  • Sarcoma
  • trabectedin
  • well-differentiated/dedifferentiated liposarcoma

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacological therapies for Liposarcoma'. Together they form a unique fingerprint.

Cite this